Abstract
Biopharmaceuticals (BFs) are molecules of biological origin and complex composition including vaccines, antibodies, hormones, clotting factors, growth factors, and cytokines that are used in addressing a variety of conditions. Despite of decades having recombinant DNA technology and sustained pharmaceutical industry development, the world faces a serious need for accessible biopharmaceuticals. Access to vaccines and other therapeutics is limited in developing countries where public resources are not sufficient to make them accessible to cope with the costs associated to their production, distribution through cold chain, and safe parenteral administration. The production of biosimilars and biobetters is opening an opportunity to improve efficacy and save resources in this field. In parallel, biotechnological alternatives for BFs production are gaining interest. In particular, genetically engineered photosynthetic organisms have been explored as biofactories and even delivery vehicles. In particular, algae species have been proposed as a low cost and convenient platform for the production of BFs. This chapter serves as an introduction to this book by presenting a brief overview of the BFs field as well as the general features of algae species that make them attractive as BFs biofactories.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aggarwal S (2009) What’s fueling the biotech engine-2008. Nat Biotechnol 27:987–993
Aggarwal S (2011) What’s fueling the biotech engine--2010 to 2011. Nat Biotechnol 29(12):1083–1089
Almo SC, Love JD (2014) Better and faster: improvements and optimization for mammalian recombinant protein production. Curr Opin Struct Biol 26:39–43
Anyaogu DC, Mortensen UH (2015) Manipulating the glycosylation pathway in bacterial and lower eukaryotes for production of therapeutic proteins. Curr Opin Biotechnol 36:122–128
Apt KE, Behrens PW (1999) Commercial developments in microalgal biotechnology. J Phycol 35(2):215–226
Apt KE, Kroth-Pancic PG, Grossman AR (1996) Stable nuclear transformation of the diatom Phaeodactylum tricornutum. Mol Gen Genet 252(5):572–579
Barclay WR, Meager KM, AbriI JR (1994) Heterotrophic production of long chain omega-3 fatty acids utilizing algae and algae-like organisms. J Appl Phycol 6(2):123–129
Barsanti L, Coltelli P, Evangelista V, Frassanito AM, Passarelli V, Vesentini N, Gualtieri P (2008) Oddities and curiosities in the algal world. In: Evangelista V, Barsanti L, Frassanito AM, Passarelli V, Gualtieri P (eds) Algal toxins: nature, occurrence, effect and detection. Springer, Dordrecht, pp 353–391
Bayne AC, Boltz D, Owen C, Betz Y, Maia G, Azadi P, Archer-Hartmann S, Zirkle R, Lippmeier JC (2013) Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity. PLoS One 8(4):e61790
Béchet Q, Chambonnière P, Shilton A, Guizard G, Guieysse B (2015) Algal productivity modeling: a step toward accurate assessments of full-scale algal cultivation. Biotechnol Bioeng 112(5):987–996
Beck A (2011) Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 3(2):107–110
Ben-Amotz A (1993) Production of b-carotene and vitamin by the halotolerant algae Dunaliella. In: Ahaway A, Zabrosky O (eds) Marine biotechnology. Plenum Press, New York, pp 411–417
Ben-Amotz A, Avron M (1990) The biotechnology of cultivating the halotolerant alga Dunaliella. Trends Biotechnol 8:121–126
Bill RM (2015) Recombinant protein subunit vaccine synthesis in microbes: a role for yeast? J Pharm Pharmacol 67(3):319–328
Boynton JE, Gillham NW, Harris EH, Hosler JP, Johnson AM, Jones AR, Randolph-Anderson B, Robertson D, Klein T, Shark K, Sandford JC (1988) Chloroplast transformation in Chlamydomonas with high velocity microprojectiles. Science 240(4858):1534–1538
Breiman A, Fawcett TW, Ghirardi ML, Mattoo AK (1992) Plant organelles contain distinct peptidylprolyl cis, trans-isomerases. J Biol Chem 267(30):21293–21296
Burki TK (2015) First biosimilar drug approved in the USA. Lancet Oncol 16(4):e161
Celik E, Calik P (2012) Production of recombinant proteins by yeast cells. Biotechnol Adv 30(5):1108–1118
Chen CY, Yeh KL, Aisyah R, Lee DJ, Chang JS (2011) Cultivation, photobioreactor design and harvesting of microalgae for biodiesel production: a critical review. Bioresour Technol 102(1):71–81
Cifuentes AS, Gonzalez M, Parra O, Zuñiga M (1996) Culture of strains of Dunaliella salina (Teodoresco 1905) in different media under laboratory conditions. Rev Chil Hist Nat 69:105–112
Daller J, Daller JR (2015) Biosimilars: a consideration of the regulations in the United States and European Union. Regul Toxicol Pharmacol pii: S0273-2300(15)30148-3. doi:10.1016/j.yrtph.2015.12.013
Dorrell RG, Smith AG (2011) Do red and green make brown?: perspectives on plastid acquisitions within chromalveolates. Eukaryot Cell 10(7):856–868
Elvin JG, Couston RG, van der Walle CF (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 440(1):83–98
Emeish S (2013) Production of natural biopharmaceuticals from the microalgae living in the dead sea. J Environ Earth Sci 3:6–15
EvaluatePharma (2012) World preview 2018 embracing the patent cliff. Technical report, Evaluate Pharma, London
Feng S, Xue L, Liu H, Lu P (2009) Improvement of efficiency of genetic transformation for Dunaliella salina by glass beads method. Mol Biol Rep 36(6):1433–1439
Feng S, Feng W, Zhao L, Gu H, Li Q, Shi K, Guo S, Zhang N (2014) Preparation of transgenic Dunaliella salina for immunization against white spot syndrome virus in crayfish. Arch Virol 159:519–525
Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C (2015) The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 1(1):e000040
Fischer S, Handrick R, Otte K (2015) The art of CHO cell engineering: a comprehensive retrospect and future perspectives. Biotechnol Adv 33(8):1878–1896
Geng D, Wang Y, Wang P, Li W, Sun Y (2003) Stable expression of hepatitis B surface antigen gene in Dunaliella salina (Chlorophyta). J Appl Phycol 15(6):451–456
Gangl D, Zedler JA, Rajakumar PD, Martinez EM, Riseley A, Włodarczyk A, Purton S, Sakuragi Y, Howe CJ, Jensen PE, Robinson C (2015) Biotechnological exploitation of microalgae. J Exp Bot 66(22):6975–6990. pii:erv426
Gimpel JA, Henríquez V, Mayfield SP (2015a) In metabolic engineering of Eukaryotic Microalgae: potential and challenges come with great diversity. Front Microbiol 6:1376
Gimpel JA, Hyun JS, Schoepp NG, Mayfield SP (2015b) Production of recombinant proteins in microalgae at pilot greenhouse scale. Biotechnol Bioeng 112(2):339–345
Gladue RM, Maxey JE (1994) Microalgal feeds for aquaculture. J Appl Phycol 6(2):131–141
Gutman BL, Niyogi KK (2004) Chlamydomonas and arabidopsis. A dynamic duo. Plant Physiol 135(2):607–610
Haustein R, de Millas C, Höer A, Häussler B (2012) Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J 1(3–4):120–126
Hempel F, Maier UG (2012) An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency. Microb Cell Fact 11:126
Hempel F, Lau J, Klingl A, Maier UG (2011) Algae as protein factories: expression of a human antibody and the respective antigen in the diatom Phaeodactylum tricornutum. PLoS One 6(12):e28424
IMS (2012) The global use of medicines: outlook through 2016. IMS health for healthcare informatics report, July 2012. http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf. Accessed 16 Mar 2014
Juárez-Montiel M, Romero-Maldonado A, Monreal-Escalante E, Becerra-Flora A, Korban SS, Rosales-Mendoza S, Jiménez-Bremont JF (2015) The corn smut (‘Huitlacoche’) as a new platform for oral vaccines. PLoS One 10(7):e0133535
Kellermann S, Green L (2002) Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 13(6):593–597
Kim J, Mayfield SP (1997) Protein disulfide isomerase as a regulator of chloroplast translational activation. Science 278(5345):1954–1957
Lauersen KJ, Vanderveer TL, Berger H, Kaluza I, Mussgnug JH, Walker VK, Kruse O (2013) Ice recrystallization inhibition mediated by a nuclear-expressed and -secreted recombinant ice-binding protein in the microalga Chlamydomonas reinhardtii. Appl Microbiol Biotechnol 97(22):9763–9772
Lauersen KJ, Huber I, Wichmann J, Baier T, Leiter A, Gaukel V, Kartushin V, Rattenholl A, Steinweg C, von Riesen L, Posten C, Gudermann F, Lütkemeyer D, Mussgnug JH, Kruse O (2015) Investigating the dynamics of recombinant protein secretion from a microalgal host. J Biotechnol 215:62–71
Lucht JM (2015) Public acceptance of plant biotechnology and GM crops. Viruses 7(8):4254–4281
Luiten EE, Akkerman I, Koulman A, Kamermans P, Reith H, Barbosa MJ, Sipkema D, Wijffels RH (2003) Realizing the promises of marine biotechnology. Biomol Eng 20(4–6):429–439
Meale SJ, Chaves AV, He ML, McAllister TA (2014) Dose–response of supplementing marine algae (Schizochytrium spp.) on production performance, fatty acid profiles, and wool parameters of growing lambs. J Anim Sci 92(5):2202–2213
Mulcahy AW, Predmore Z, Mattke S (2014) The cost savings potential of biosimilar drugs in the United States. RAND Corporation, Santa Monica
Olaizola M (2003) Commercial development of microalgal biotechnology: from the test tube to the marketplace. Biomol Eng 20:459–466
Ornes S (2015) Core concepts: biosimilars. Proc Natl Acad Sci U S A 112(50):15261–15262
Overton TW (2014) Recombinant protein production in bacterial hosts. Drug Discov Today 19(5):590–601
Pépin J, Abou Chakra CN, Pépin E, Nault V, Valiquette L (2014) Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS One 9(6):e99677
Pröschold T, Marin B, Schlösser UG, Melkonian M (2001) Molecular phylogeny and taxonomic revision of Chlamydomonas (Chlorophyta). I. Emendation of Chlamydomonas Ehrenberg and Chloromonas Gobi, and description of Oogamochlamys gen. nov. and Lobochlamys gen. nov. Protist 152(4):265–300
Rader RA (2013) FDA biopharmaceutical product approvals and trends in 2012. BioProcess Int 11(3):18–27
Rasala BA, Lee PA, Shen Z, Briggs SP, Mendez M, Mayfield SP (2012) Robust expression and secretion of Xylanase1 in Chlamydomonas reinhardtii by fusion to a selection gene and processing with the FMDV 2A peptide. PLoS One 7(8):e43349
Ren LJ, Ji XJ, Huang H, Qu L, Feng Y, Tong QQ, Ouyang PK (2010) Development of a stepwise aeration control strategy for efficient docosahexaenoic acid production by Schizochytrium sp. Appl Microbiol Biotechnol 87(5):1649–1656
Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, Lakatos PL (2015) Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 21(6):1728–1737
Reski R, Parsons J, Decker EL (2015) Moss-made pharmaceuticals: from bench to bedside. Plant Biotechnol J 13(8):1191–1198
Richmond A, Soeder CJ (1986) Microalgaculture. Crit Rev Biotechnol 4:369–438
Rochaix JD (1995) Chlamydomonas reinhardtii as the photosynthetic yeast. Annu Rev Genet 29:209–230
Rosales-Mendoza S, Paz-Maldonado LM, Soria-Guerra RE (2012) Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives. Plant Cell Rep 31(3):479–494
Rosales-Mendoza S, Angulo C, Meza B (2015) Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol 34(2):124–136. pii:S0167-7799(15)00247-4
Round FE, Crawford RM, Mann DG (1990) The diatoms: biology and morphology of the genera. Cambridge Univ Press, Cambridge
Scaife MA, Nguyen GT, Rico J, Lambert D, Helliwell KE, Smith AG (2015) Establishing Chlamydomonas reinhardtii as an industrial biotechnology host. Plant J 82(3):532–546
Schellekens H (2004) How similar ‘biosimilars’ need to be? Nat Biotechnol 22(11):1357–1359
Schroda M (2004) The Chlamydomonas genome reveals its secrets: chaperone genes and the potential roles of their gene products in the chloroplast. Photosynth Res 82(3):221–240
Shaaltiel Y, Gingis-Velitski S, Tzaban S, Fiks N, Tekoah Y, Aviezer D (2015) Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher’s disease. Plant Biotechnol J 13(8):1033–1040
Shellenkens H (2004) When biotech proteins go off-patent. Trends Biotechnol 22(8):406–410
Show KY, Lee DJ, Tay JH, Lee TM, Chang JS (2015) Microalgal drying and cell disruption--recent advances. Bioresour Technol 184:258–266
Singh SM, Panda AK (2005) Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng 99(4):303–310
Spoehr HA, Milner HW (1949) The chemical composition of Chlorella; effect of environmental conditions. Plant Physiol 24(1):120–149
Streatfield SJ, Kushnir N, Yusibov V (2015) Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. Plant Biotechnol J 13(8):1136–1159
Strohl WR (2015) Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29(4):215–239
Tada M, Tatematsu K, Ishii-Watabe A, Harazono A, Takakura D, Hashii N, Sezutsu H, Kawasaki N (2015) Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori). MAbs 7(6):1138–1150
Tekoah Y, Shulman A, Kizhner T, Ruderfer I, Fux L, Nataf Y, Bartfeld D, Ariel T, Gingis-Velitski S, Hanania U, Shaaltiel Y (2015) Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience. Plant Biotechnol J 13(8):1199–1208
Terpe K (2006) Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 72(2):211–222
Varshney P, Mikulic P, Vonshak A, Beardall J, Wangikar PP (2015) Extremophilic micro-algae and their potential contribution in biotechnology. Bioresour Technol 184:363–372
Warburg O (1919) Über die Geschwindigkeit der photochemischen Kohlensaurezersetzung in lebenden Zellen. Biochem Z 100:230
Yamaguchi K (1997) Recent advances in microalgal bioscience in Japan, with special reference to utilization of biomass and metabolites: a review. J Appl Phycol 8(6):487–502
Yokoyama R, Honda D (2007) Taxonomic rearrangement of the genus Schizochytrium sensu lato based on morphology, chemotaxonomic characteristics, and 18S rRNA gene phylogeny (Thraustochytriaceae, Labyrinthulomycetes): emendation for Schizochytrium and erection of Aurantiochytrium and Oblongichytrium. Gen Nov Mycoscience 48(4):199–211
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rosales-Mendoza, S. (2016). The Biopharmaceuticals Field and Algae as Expression Hosts. In: Algae-Based Biopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-319-32232-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-32232-2_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-32230-8
Online ISBN: 978-3-319-32232-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)